

# Effectiveness of the trivalent influenza vaccine

Michael R. Kolber MD CCFP MSc   Darren Lau PhD   Dean Eurich PhD   Christina Korownyk MD CCFP

### Clinical question

Does the seasonal trivalent influenza vaccine (flu shot) prevent influenza or its complications in adults and seniors?

### Bottom line

For healthy adults, the flu shot reduces the influenza rate when the vaccine is well matched (number needed to treat [NNT] of 12 to 37). A poorly matched vaccine has diminished effectiveness. For community-dwelling seniors, the NNT to prevent 1 case of influenza is 40. The flu shot has not been shown to decrease hospitalizations. Evidence that the flu shot decreases mortality is likely biased.

### Evidence

For those aged 16 to 65 years:

- Meta-analysis of 17 flu-shot RCTs in 38 800 adults.<sup>1</sup>
  - Influenza with well-matched vaccine (matches  $\geq 80\%$  of circulating virus) = 1.2% and with control = 3.9%; NNT = 37.
  - Influenza with poor or uncertain vaccine match = 1.1% and with control = 2.4%; NNT = 77.
  - Number of sick days decreased (by about half a day) when vaccine was matched.
  - Hospitalization (2 trials) and pneumonia rates (1 trial) were not affected and mortality rates were not reported.
  - Limitations: most studies examined 1 influenza season, many included health care workers or children, and some examined epidemics from 30 years ago.
- Systematic review of 8 RCTs reported NNT = 67 for flu shot.<sup>2</sup>
- The most generalizable RCT involved American factory workers during 2 influenza seasons.<sup>3</sup>
  - Influenza with well-matched vaccine = 1.4% and with placebo = 10.2%; NNT = 12.
  - No statistical difference for poor vaccine match.

For seniors aged 65 years or older:


- Authors of a meta-analysis concluded they were unable to determine the flu shot's effectiveness in seniors.<sup>4</sup>
- The highest-quality flu-shot RCT in 1838 community-dwelling seniors found influenza with vaccine = 1.7% and with placebo = 4.2%; NNT = 40.<sup>5</sup>

### Context

- The flu shot is updated annually to match predicted strains and, in Canada, was well matched in 7 of the past 14 years (calculated with data from [www.phac.aspc.gc.ca/fluwatch](http://www.phac.aspc.gc.ca/fluwatch)).
- Localized (pain) and systemic (fever or myalgia) adverse events are more common with the flu shot than with placebo.<sup>1,4</sup>

- Observational evidence that the flu shot reduces hospitalizations and mortality<sup>6</sup> is biased by healthier patients more often choosing vaccination.<sup>4,7</sup>
- Canadian guidelines recommend universal flu shots.<sup>8</sup>

### Implementation

Influenza is prevented primarily through hand washing and vaccination.<sup>9</sup> In the past, only about 30% of Canadians and 40% of health care workers received flu shots.<sup>10,11</sup> Influenza treatment is primarily supportive. The apparent effectiveness of neuraminidase inhibitors such as oseltamivir in treating influenza (symptom resolution about 1 day earlier; 6.7 vs 5.8 days) is likely biased; most oseltamivir trials are not published and there is selective reporting of adverse events.<sup>12,13</sup> To increase vaccination, public campaigns and personal reminders might be beneficial.<sup>12</sup> Patient education addressing myths (eg, the flu shot causes influenza; the vaccine is unsafe) is essential. 

**Dr Kolber** is Associate Professor in the Department of Family Medicine at the University of Alberta in Edmonton. **Dr Lau** is a medical-doctoral student in the Faculty of Medicine and Dentistry at the University of Alberta. **Dr Eurich** is Associate Professor in the Li Ka Shing Centre for Health Research Innovation at the University of Alberta. **Dr Korownyk** is Assistant Professor in the Department of Family Medicine at the University of Alberta.

The opinions expressed in Tools for Practice articles are those of the authors and do not necessarily mirror the perspective and policy of the Alberta College of Family Physicians.

### References

1. Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E. Vaccines for preventing influenza in healthy adults. *Cochrane Database Syst Rev* 2010;(7):CD001269.
2. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. *Lancet Infect Dis* 2012;12(1):36-44.
3. Bridges CB, Thompson WW, Meltzer MI, Reeve GR, Talamonti WJ, Cox NJ, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. *JAMA* 2000;284(13):1655-63.
4. Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorming S, Thomas RE. Vaccines for preventing influenza in the elderly. *Cochrane Database Syst Rev* 2010;(2):CD004876.
5. Govaert TME, Thijs CTMCN, Masurel N, Sprenger MJW, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. *JAMA* 1994;272(21):1661-5.
6. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. *N Engl J Med* 2007;357(14):1373-81.
7. Eurich DT, Marrie TJ, Johnstone J, Majumdar SR. Mortality reduction with influenza vaccine in patients with pneumonia outside 'flu' season: pleiotropic benefits or residual confounding? *American J Resp Crit Care Med* 2008;178(5):527-33.
8. National Advisory Committee on Immunization. Statement on seasonal influenza vaccine for 2013-2014. *Can Commun Dis Rep Wkly* 2013;39(ACS-4):1-37.
9. Morabia A, Costanza MC. Handwashing against hospitalization for influenza: time for PHIR? *Prev Med* 2012;54(6):369-70.
10. Johansen H, Sambell C, Zhao W. Flu shots—national and provincial/territorial trends. *Health Rep* 2006;17(2):43-8.
11. Lam PP, Chambers LW, Pierrynowski MacDougall DM, McCarthy AE. Seasonal influenza vaccination campaigns for health care personnel: systematic review. *CMAJ* 2010;182(12):E542-8.
12. Lau D, Hu J, Majumdar SR, Storie DA, Rees SE, Johnson JA. Interventions to improve influenza and pneumococcal vaccination rates among community-dwelling adults: a systematic review and meta-analysis. *Ann Fam Med* 2012;10(6):538-46.
13. Jefferson T, Jones MA, Doshi P, Del Mar CB, Heneghan CJ, Hama R, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. *Cochrane Database Syst Rev* 2012;(1):CD008965.



Tools for Practice articles in *Canadian Family Physician* (CFP) are adapted from articles published on the Alberta College of Family Physicians (ACFP) website, summarizing medical evidence with a focus on topical issues and practice-modifying information. The ACFP summaries and the series in CFP are coordinated by Dr G. Michael Allan, and the summaries are co-authored by at least 1 practising family physician and are peer reviewed. Feedback is welcome and can be sent to [toolsforpractice@cfpc.ca](mailto:toolsforpractice@cfpc.ca). Archived articles are available on the ACFP website: [www.acfp.ca](http://www.acfp.ca).